Rechercher | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Affichage: 2 résultats.

- Article de périodique
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe, Steven W Shima, Midori Lehle, Michaela Shapiro, Amy Chebon, Sammy Fukutake, Katsuyuki Key, Nigel S Portron, Agnès Schmitt, Christophe Podolak-Dawidziak, Maria Selak Bienz, Nives Hermans, Cédric[UCL] Campinha-Bacote, Avrita Kiialainen, Anna Peerlinck, Kathelijne Levy, Gallia G Jiménez-Yuste, Victor (2019) The Lancet. Haematology — Vol. 6, no.6, p. e295-e305 (2019)
- Article de périodique
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier, Claude Mahlangu, Johnny Lehle, Michaela Chowdary, Pratima Catalani, Olivier Bernardi, Ronald J Jiménez-Yuste, Víctor Beckermann, Benjamin M Schmitt, Christophe Ventriglia, Giuliana Windyga, Jerzy d'Oiron, Roseline Moorehead, Paul Koparkar, Sunita Teodoro, Vanda Shapiro, Amy D Oldenburg, Johannes Hermans, Cédric[UCL] (2023) The Lancet. Haematology — Vol. 10, no.3, p. e168-e177 (2023)